<DOC>
	<DOCNO>NCT00422058</DOCNO>
	<brief_summary>This trial conduct Europe . The purpose 20-week trial investigate efficacy liraglutide induce body weight loss purpose extension evaluate long term safety tolerability liraglutide . Trial follow trial period : A 20-week randomised , double-blind , placebo-controlled , six-armed parallel-group , multi-centre , multinational trial open label orlistat comparator arm follow 84 week extension period .</brief_summary>
	<brief_title>The Effect Liraglutide Body Weight Obese Subjects Without Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Nutrition Disorders</mesh_term>
	<mesh_term>Orlistat</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Body Mass Index ( BMI ) great equal 30.0 less equal 40.0 kg/m2 Stable body weight ( less 5 % selfreported change within last 3 month ) Obesity induced drug treatment Use approve drug weight lower intervention ( e.g . orlistat , sibutramin , rimonabant ) within last 3 month prior enter trial Type 1 type 2 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>